FDA Accepts IND of NK Cell Therapy for HER2 Positive Solid Tumors

Jan 09, 2020

|

NEW YORK – Biotech company Acepodia said Thursday that the US Food and Drug Administration accepted the investigational new drug application for its new antibody-cell conjugate based immunotherapy, ACE1702, for patients with HER2-expressing solid tumors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

FDA Accepts IND of NK Cell Therapy for HER2 Positive Solid Tumors

To read the full story....

Breaking News

Blueprint Medicine's Ayvakyt Garners Conditional European Commission Authorization in GIST

BMS's Opdivo Prolongs Disease-Free Survival as Adjuvant Treatment for Patients With Bladder Cancer

Blueprint Medicines to Pursue Ayvakit Approval in Cancer-Causing Mast Cell Disorder

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

What's Popular?

Growing Data on Vitrakvi Demonstrate Enduring Activity Across Variety of NTRK-Positive Tumor Types

Conflicting ESMO Data Raise Questions About Role of CDK4/6 Inhibitors in Adjuvant Breast Cancer

FDA Accepts Pfizer's sNDA for Xalkori in Rare ALK-Positive Pediatric Leukemia Indication

Ideaya, Pfizer Expand Collaboration to Study IDE196, Xalkori

Roche's Ipatasertib, Anti-Androgen Therapy Improves Outcomes in Prostate Cancer With PTEN Loss

Sponsorships